DK2981255T3 - Terapeutiske anvendelser af empagliflozin - Google Patents

Terapeutiske anvendelser af empagliflozin Download PDF

Info

Publication number: DK2981255T3
Authority: DK; Denmark
Prior art keywords: empagliflozin; therapeutic uses; therapeutic
Prior art date: 2013-04-05

Application number

DK14715274.8T

Other languages

English (en)

Inventor

Uli Christian Broedl

David Cherney

Andreas Daiber

Eynatten Maximilian Von

Gabriel Woojai Kim

Eric Williams Mayoux

Thomas Muenzel

Bruce A Perkins

Afshin Salsali

Nima Soleymanlou

Hans-Juergen Woerle

Odd-Erik Johansen

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-04-05

Filing date

2014-04-03

Publication date

2022-11-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51787227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2981255(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-04-03 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2022-11-14 Application granted granted Critical

2022-11-14 Publication of DK2981255T3 publication Critical patent/DK2981255T3/da

Links

OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 title 1
229960003345 empagliflozin Drugs 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Toxicology (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Biochemistry (AREA)
Urology & Nephrology (AREA)
Biophysics (AREA)
Hospice & Palliative Care (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

DK14715274.8T 2013-04-05 2014-04-03 Terapeutiske anvendelser af empagliflozin DK2981255T3 (da)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US201361808807P	2013-04-05	2013-04-05
CA2812016A CA2812016A1 (en)	2013-04-05	2013-04-10	Pharmaceutical composition, methods for treating and uses thereof
US201361823041P	2013-05-14	2013-05-14
US201361835809P	2013-06-17	2013-06-17
US201361835811P	2013-06-17	2013-06-17
US201461942301P	2014-02-20	2014-02-20
PCT/EP2014/056655 WO2014161918A1 (en)	2013-04-05	2014-04-03	Therapeutic uses of empagliflozin

Publications (1)

Publication Number	Publication Date
DK2981255T3 true DK2981255T3 (da)	2022-11-14

Family

ID=51787227

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK14715274.8T DK2981255T3 (da)	2013-04-05	2014-04-03	Terapeutiske anvendelser af empagliflozin

Country Status (20)

Country	Link
US (2)	US20240156848A1 (da)
EP (2)	EP4119136A1 (da)
JP (4)	JP6325084B2 (da)
KR (3)	KR20210131442A (da)
CN (3)	CN105263485A (da)
AU (2)	AU2014247091B2 (da)
CA (2)	CA2812016A1 (da)
DK (1)	DK2981255T3 (da)
EA (1)	EA035181B1 (da)
ES (1)	ES2930655T3 (da)
FI (1)	FI2981255T3 (da)
HR (1)	HRP20221368T1 (da)
HU (1)	HUE060721T2 (da)
IL (2)	IL276289B (da)
LT (1)	LT2981255T (da)
MX (2)	MX378422B (da)
PL (1)	PL2981255T3 (da)
PT (1)	PT2981255T (da)
RS (1)	RS63721B1 (da)
WO (1)	WO2014161918A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY161472A (en)	2009-02-13	2017-04-14	Boehringer Ingelheim Int	Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
HRP20190101T1 (hr)	2013-04-05	2019-03-08	Boehringer Ingelheim International Gmbh	Terapeutske uporabe empagliflozina
CA2812016A1 (en)	2013-04-05	2014-10-05	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en)	2013-04-05	2014-10-09	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en)	2013-04-05	2014-10-05	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en)	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
KR102309654B1 (ko)	2013-04-18	2021-10-08	베링거 인겔하임 인터내셔날 게엠베하	약제학적 조성물, 치료 방법 및 이의 용도
ES2900843T3 (es) *	2014-05-16	2022-03-18	Astrazeneca Ab	Método para suprimir la secreción de glucagón de un inhibidor de sglt2
WO2016174155A1 (en)	2015-04-30	2016-11-03	Boehringer Ingelheim International Gmbh	Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction
EP3362055B1 (en)	2015-10-15	2023-01-18	Boehringer Ingelheim International GmbH	Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
CN118286238A (zh) *	2016-03-16	2024-07-05	勃林格殷格翰国际有限公司	包含恩格列净的药物组合物及其用途
CA3039745A1 (en)	2016-11-10	2018-05-17	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
TWI835735B (zh) *	2017-06-12	2024-03-21	比利時商健生藥品公司	減少或預防第ii型糖尿病患者中心血管事件之方法
MY210547A (en) *	2017-11-30	2025-09-30	Idorsia Pharmaceuticals Ltd	Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
WO2020016335A1 (en)	2018-07-19	2020-01-23	Astrazeneca Ab	Methods of treating hfpef employing dapagliflozin and compositions comprising the same
CN109846898A (zh) *	2019-02-01	2019-06-07	同济大学	恩格列净在制备治疗和/或预防心肌梗死的药物中的应用
BR112021022682A2 (pt) *	2019-05-14	2022-02-22	Provention Bio Inc	Métodos e composições para prevenir diabetes do tipo 1
US20220257626A1 (en) *	2019-07-23	2022-08-18	Novartis Ag	Treatment comprising sglt inhibitors
JOP20200098A1 (ar)	2019-08-30	2021-02-28	Astrazeneca Ab	طرق علاج الفشل القلبي مع كسر قذفي منخفض بواسطة داباجليفلوزين
CN115300627B (zh) *	2021-05-08	2024-01-26	中南大学湘雅医院	钠-葡萄糖共转运蛋白2抑制剂的应用、一种药物组合物及其应用
WO2022251253A1 (en)	2021-05-24	2022-12-01	Provention Bio, Inc.	Methods for treating type 1 diabetes
CN115969844B (zh) *	2021-12-28	2024-04-02	首都医科大学附属北京同仁医院	Nox2特异性抑制剂在制备视网膜变性药物中的应用
JP2025541481A (ja) *	2022-12-20	2025-12-18	ティーエイチファームコーポレーション	ナトリウム－グルコース共輸送体－２阻害剤およびアンジオテンシンｉｉ受容体遮断剤を含む非アルコール性脂肪性肝疾患の予防または治療用薬学的組成物
EP4640223A1 (en) *	2022-12-20	2025-10-29	THPharm Corp.	Pharmaceutical composition for prevention or treatment of cardiovascular disease, comprising sodium-glucose cotransporter-2 inhibitor and angiotensin ii receptor blocker
CN116212023A (zh) *	2022-12-30	2023-06-06	中山大学孙逸仙纪念医院	Sglt2抑制剂在制备预防或/和治疗血管钙化药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA91546C2 (uk) *	2005-05-03	2010-08-10	Бьорінгер Інгельхайм Інтернаціональ Гмбх	КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
TW200817424A (en) *	2006-08-04	2008-04-16	Daiichi Sankyo Co Ltd	Benzylphenyl glucopyranoside derivatives
PE20090938A1 (es) *	2007-08-16	2009-08-08	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
MY161472A (en) *	2009-02-13	2017-04-14	Boehringer Ingelheim Int	Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
PL2395983T3 (pl) *	2009-02-13	2020-09-07	Boehringer Ingelheim International Gmbh	Kompozycja farmaceutyczna zawierająca inhibitor sglt2, inhibitor dpp-iv i ewentualnie dalszy środek przeciwcukrzycowy oraz jej zastosowania
UY32427A (es)	2009-02-13	2010-09-30	Boheringer Ingelheim Internat Gmbh	Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
MX345494B (es)	2009-02-13	2017-02-02	Boehringer Ingelheim Int Gmbh *	Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, dosificación farmacéutica de la misma, procesos para su preparación y usos de la misma para el control glucemico mejorado en un paciente.
US10610489B2 (en) *	2009-10-02	2020-04-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US20120283169A1 (en) *	2010-11-08	2012-11-08	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
AR083878A1 (es) *	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US20130035281A1 (en) *	2011-02-09	2013-02-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
UY33937A (es)	2011-03-07	2012-09-28	Boehringer Ingelheim Int	Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
US9192617B2 (en)	2012-03-20	2015-11-24	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) *	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
CA2812016A1 (en)	2013-04-05	2014-10-05	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) *	2013-04-05	2014-10-09	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
CN118286238A (zh)	2016-03-16	2024-07-05	勃林格殷格翰国际有限公司	包含恩格列净的药物组合物及其用途

2013
- 2013-04-10 CA CA2812016A patent/CA2812016A1/en not_active Abandoned
2014
- 2014-04-03 CN CN201480031475.5A patent/CN105263485A/zh active Pending
- 2014-04-03 KR KR1020217034100A patent/KR20210131442A/ko not_active Ceased
- 2014-04-03 WO PCT/EP2014/056655 patent/WO2014161918A1/en not_active Ceased
- 2014-04-03 EA EA201500996A patent/EA035181B1/ru not_active IP Right Cessation
- 2014-04-03 HR HRP20221368TT patent/HRP20221368T1/hr unknown
- 2014-04-03 CN CN201811558246.5A patent/CN109512831A/zh active Pending
- 2014-04-03 HU HUE14715274A patent/HUE060721T2/hu unknown
- 2014-04-03 AU AU2014247091A patent/AU2014247091B2/en active Active
- 2014-04-03 PT PT147152748T patent/PT2981255T/pt unknown
- 2014-04-03 JP JP2016505815A patent/JP6325084B2/ja active Active
- 2014-04-03 ES ES14715274T patent/ES2930655T3/es active Active
- 2014-04-03 FI FIEP14715274.8T patent/FI2981255T3/fi active
- 2014-04-03 PL PL14715274.8T patent/PL2981255T3/pl unknown
- 2014-04-03 CA CA2908621A patent/CA2908621C/en active Active
- 2014-04-03 KR KR1020157031843A patent/KR102318207B1/ko active Active
- 2014-04-03 MX MX2015013948A patent/MX378422B/es unknown
- 2014-04-03 DK DK14715274.8T patent/DK2981255T3/da active
- 2014-04-03 EP EP22188586.6A patent/EP4119136A1/en active Pending
- 2014-04-03 MX MX2020013740A patent/MX2020013740A/es unknown
- 2014-04-03 LT LTEPPCT/EP2014/056655T patent/LT2981255T/lt unknown
- 2014-04-03 EP EP14715274.8A patent/EP2981255B1/en active Active
- 2014-04-03 KR KR1020237016366A patent/KR20230074293A/ko active Pending
- 2014-04-03 CN CN201811554457.1A patent/CN110075301A/zh active Pending
- 2014-04-03 RS RS20221029A patent/RS63721B1/sr unknown
2019
- 2019-04-12 AU AU2019202568A patent/AU2019202568B2/en active Active
2020
- 2020-03-04 JP JP2020036762A patent/JP7541641B2/ja active Active
- 2020-07-26 IL IL276289A patent/IL276289B/en unknown
2021
- 2021-10-24 IL IL287516A patent/IL287516B1/en unknown
2022
- 2022-02-18 JP JP2022023891A patent/JP2022069476A/ja active Pending
2024
- 2024-01-25 US US18/422,333 patent/US20240156848A1/en not_active Abandoned
- 2024-02-16 JP JP2024021883A patent/JP2024059725A/ja active Pending
2025
- 2025-07-21 US US19/274,809 patent/US20250345352A1/en active Pending

Also Published As

Publication number	Publication date
CN109512831A (zh)	2019-03-26
KR20230074293A (ko)	2023-05-26
LT2981255T (lt)	2022-11-25
CA2908621C (en)	2022-08-16
EP2981255A1 (en)	2016-02-10
CA2812016A1 (en)	2014-10-05
AU2014247091A1 (en)	2015-09-17
KR102318207B1 (ko)	2021-10-28
JP2020109100A (ja)	2020-07-16
MX378422B (es)	2025-03-10
AU2019202568B2 (en)	2021-04-01
EP4119136A1 (en)	2023-01-18
JP2022069476A (ja)	2022-05-11
JP2024059725A (ja)	2024-05-01
IL276289A (en)	2020-09-30
EA035181B1 (ru)	2020-05-12
US20240156848A1 (en)	2024-05-16
PT2981255T (pt)	2022-11-21
HRP20221368T1 (hr)	2023-01-06
US20250345352A1 (en)	2025-11-13
IL276289B (en)	2022-02-01
EP2981255B1 (en)	2022-09-14
MX2020013740A (es)	2022-10-27
PL2981255T3 (pl)	2023-01-09
EA201500996A1 (ru)	2016-04-29
CN105263485A (zh)	2016-01-20
CA2908621A1 (en)	2014-10-09
ES2930655T3 (es)	2022-12-20
IL287516A (en)	2021-12-01
AU2019202568A1 (en)	2019-05-02
IL287516B1 (en)	2023-07-01
KR20150138859A (ko)	2015-12-10
FI2981255T3 (fi)	2022-12-15
KR20210131442A (ko)	2021-11-02
HUE060721T2 (hu)	2023-04-28
WO2014161918A1 (en)	2014-10-09
JP6325084B2 (ja)	2018-05-16
JP2016515599A (ja)	2016-05-30
AU2014247091B2 (en)	2019-01-17
MX2015013948A (es)	2016-07-20
RS63721B1 (sr)	2022-12-30
CN110075301A (zh)	2019-08-02
JP7541641B2 (ja)	2024-08-29

Publication	Publication Date	Title
DK2968208T3 (da)	2022-08-22	Behandling af kataplexi
LT2981255T (lt)	2022-11-25	Empagliflozino terapiniai panaudojimo būdai
HRP20190101T1 (hr)	2019-03-08	Terapeutske uporabe empagliflozina
DK2961388T3 (da)	2019-07-08	Kombinationer af lægemidler
DK3080100T3 (da)	2023-02-06	Hæmmere af lysinspecifik demethylase-1
DK2970954T3 (da)	2019-01-02	Modifikation af polypeptider
DK3087183T3 (da)	2020-09-14	Modulation af angiopoietin-3-lignende ekspression
DK2845905T3 (da)	2021-06-14	Fremstilling af oligosaccharider
DK3021838T3 (da)	2020-08-24	Behandling af fedme
HRP20180684T1 (hr)	2018-06-01	Kombinacija lijekova
EP2982689A4 (en)	2016-11-02	FC-REGIONS-VARIATIONS
PL2970412T3 (pl)	2022-11-14	Aktywacja bioluminescencji przez dopełnienie strukturalne
DK3626270T3 (da)	2024-01-15	Behandling af kardiovaskulære sygdomme
DK2965026T3 (da)	2019-10-28	Generering af slushice
PT2953948T (pt)	2017-12-12	Antagonistas de integrina fluorada
DK3003306T3 (da)	2020-11-30	Gentagen indgivelse af ikke-immunosupressive antigenspecifikke immunterapeutika
LT3007726T (lt)	2020-09-10	Tautopatijos gydymo būdai
DK2961378T3 (da)	2019-11-25	Fremgangsmåder til behandlingen af mitochondrisk sygdom
DK3060226T3 (da)	2021-03-01	Fagterapi af pseudomonasinfektioner
DK3024519T3 (da)	2020-10-26	Destruktion af hypodermiske kanyler
PL2991633T3 (pl)	2019-10-31	Terapia bakteriofagami
EP2945942A4 (en)	2016-08-03	Voriconazole IMMUNOASSAY
DK3511004T3 (da)	2024-09-23	Kombineret præparat til behandling af cancer
DK3297619T3 (da)	2022-08-15	Terapeutiske anvendelser af L-4-chlorkynurenin
EP2988738A4 (en)	2016-11-09	THERAPEUTIC INDICATIONS OF KINASE INHIBITORS